Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1968 2
1973 1
1974 1
1978 3
1979 2
1980 1
1983 1
1986 3
1988 1
1989 2
1990 1
1991 2
1992 2
1993 1
1994 3
1995 5
1996 3
1998 2
1999 3
2000 2
2003 3
2004 2
2005 5
2006 5
2007 6
2008 10
2009 5
2010 6
2011 8
2012 10
2013 3
2014 1
2015 5
2016 1
2019 5
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Younossi ZM, et al. Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5. Lancet. 2019. PMID: 31813633 Free article. Clinical Trial.
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Sanyal AJ, et al. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. N Engl J Med. 2010. PMID: 20427778 Free PMC article. Clinical Trial.
Genetic influences in nonalcoholic fatty liver disease.
Merriman RB, Aouizerat BE, Bass NM. Merriman RB, et al. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S30-3. doi: 10.1097/01.mcg.0000168643.16074.19. J Clin Gastroenterol. 2006. PMID: 16540764 Review.
Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
Serper M, Parikh ND, Thiele G, Ovchinsky N, Mehta S, Kuo A, Ho C, Kanwal F, Volk M, Asrani SK, Ghabril MS, Lake JR, Merriman RB, Morgan TR, Tapper EB. Serper M, et al. Among authors: merriman rb. Hepatology. 2022 Jul;76(1):251-274. doi: 10.1002/hep.32313. Epub 2022 Jan 22. Hepatology. 2022. PMID: 34990516 Free PMC article. Review.
Ethnicity and nonalcoholic fatty liver disease.
Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Bambha K, et al. Hepatology. 2012 Mar;55(3):769-80. doi: 10.1002/hep.24726. Hepatology. 2012. PMID: 21987488 Free PMC article.
112 results